Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica


Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply L

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Convatec Group PLC: Scrip Dividend - Total Issued Shares
Convatec Group PLC: Scrip Dividend - Total Issued Shares
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial


ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announces that it is partnering with the U.S. Biomedical Advanced Research and Development

Premier, Inc. Realigns Leadership Team and Promotes Key Executives to Accelerate Innovation and Profitable Growth: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Realigns Leadership Team and Promotes Key Executives to Accelerate Innovation and Profitable Growth


Premier, Inc. (NASDAQ: PINC) (“Premier” or the “Company”), a leading technology-enabled healthcare improvement company, today announced three executive promotions that strategically position the

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:




  • Morgan Stanley 21st Annual Global Healthcare

Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer


Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River and PathoQuest Announce Publication of a Head-to-Head Study Validating Proprietary Next Generation Sequencing Viral Safety Assay as a Reliable In Vitro Alternative to Animal Testing Methods


Charles River Laboratories International, Inc. (NYSE: CRL) and PathoQuest SAS, a leader in the development and provision of next-generation sequencing (NGS) testing services for biopharmaceuticals

ICON plc to Present at the Baird Global Healthcare Conference: https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON plc to Present at the Baird Global Healthcare Conference


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Baird Global

Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
Acadia Healthcare to Participate in 2023 Wells Fargo Healthcare Conference: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare to Participate in 2023 Wells Fargo Healthcare Conference


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the 2023 Wells Fargo Healthcare Conference, September 6 - 8, 2023, in Boston.



In connection

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: TR-1 Notification of Major Holdings
Convatec Group PLC: TR-1 Notification of Major Holdings
Convatec Group PLC: TR-1 Notification of Major Holdings
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies


Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Evaluating Tumor Treating Fields Therapy in Platinum-resistant Ovarian Cancer


Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with

Convatec Group PLC: Scrip Dividend – Calculation Price
Convatec Group PLC: Scrip Dividend – Calculation Price
Convatec Group PLC: Scrip Dividend – Calculation Price
Novocure to Participate in Upcoming Investor Conferences: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure to Participate in Upcoming Investor Conferences


Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief

Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
LivaNova to Present at the Baird Global Healthcare Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present at the Baird Global Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present in a fireside chat at

Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Announces Plasmid Manufacturing Collaboration with Fondazione Telethon


Charles River Laboratories International, Inc. (NYSE: CRL), today announced a High Quality (HQ) plasmid manufacturing collaboration with Fondazione Telethon. The rare disease organization will